Bris­tol My­ers set­tles an­ti-gener­ic HIV drug scheme al­le­ga­tions for al­most $11M

Al­though Bris­tol My­ers Squibb isn’t ad­mit­ting to any wrong­do­ing, the bio­phar­ma com­pa­ny agreed to pay al­most $11 mil­lion to set­tle al­le­ga­tions filed in a Cal­i­for­nia dis­trict court that the com­pa­ny took part in an un­law­ful scheme with oth­er phar­ma com­pa­nies like Gilead and Janssen to pro­tect their HIV drug prof­its while slow­ing gener­ic com­pe­ti­tion.

Specif­i­cal­ly, the com­plaint filed in 2019 al­leged that as im­mi­nent gener­ic com­pe­ti­tion to Gilead’s HIV drugs — Viread, Emtri­va, Tru­va­da and oth­ers — ap­proached, Gilead agreed with each of BMS, Janssen, and Japan To­bac­co to cre­ate and mar­ket FD­Cs that com­bined their third agents with Gilead’s NR­TIs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER